Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06928142 · ClinicalTrials.gov registry record · Phase 2
A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
A Phase 2 study of Sjogren Disease, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Active
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
- 20
- Study locations
NCT06928142: Active Phase 2 study of Sjogren Disease, sponsored by Otsuka Pharmaceutical Development & Commercialization.
NCT06928142 is a Phase 2 study of Sjogren Disease that is active but no longer recruiting, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 83 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (38% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06928142, a Phase 2 study of Sjogren Disease, is active but no longer recruiting, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 2 study to evaluate the effects of sibeprenlimab 400 mg administered subcutaneously (SC) every 4 (Q4) weeks as an add-on to background treatment in participants with Sjögren's disease.
Primary Outcome
Higher scores on the ESSDAI indicate a worse outcome, as they reflect higher disease activity. Minimum value is 0 and the maximum value is 123.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Sibeprenlimab
Study Locations (20)
Texas
- Allen Arthritis - Allen
- Tekton Research, LLC - Austin
- Advanced Rheumatology of Houston - Houston
- Accurate Clinical Research - Houston - Houston
- Accurate Clinical Management, LLC - Katy
- R & H Clinical Research - Katy
Florida
- Bay Area Arthritis and Osteoporosis - Brandon
- Clinical Research of West Florida Inc - Clearwater
- GNP Research - Florida - Cooper City
- Vantage Clinical Trials - Tampa - ClinEdge - PPDS - Tampa
California
- Medvin Clinical Research - Riverside - Riverside
- Medvin Clinical Research - Tujunga - Tujunga
Illinois
- OrthoIllinois, LTD - Rockford
- Arnold Arthritis and Rheumatology - Skokie
Louisiana
- Ochsner Clinic Foundation - Baton Rouge
Massachusetts
- Tufts University School of Dental Medicine - Boston
New Mexico
- Albuquerque Center for Rheumatology - Albuquerque
New York
- Bradenton Research Center Inc - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2025-04-23 |
| Est. Completion | 2027-06-04 |
| Phase | Phase 2 |
What the registry record for NCT06928142 still lists
NCT06928142 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (38% lower).
The record links to 1 condition, with Sjogren Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06928142 names 20 study sites across 10 states, led by Texas, Florida, California.
Frequently Asked Questions
What is clinical trial NCT06928142 about?
NCT06928142 is a clinical study titled "A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's". This is a phase 2 study to evaluate the effects of sibeprenlimab 400 mg administered subcutaneously (SC) every 4 (Q4) weeks as an add-on to background treatment in participants with Sjögren's disease.
What is the current status of trial NCT06928142?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2025-04-23. Estimated completion is 2027-06-04.
What conditions does trial NCT06928142 study?
This clinical trial studies the following conditions: Sjogren Disease.
What interventions are being tested in trial NCT06928142?
The interventions under investigation include: Placebo (OTHER), Sibeprenlimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06928142?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06928142 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sjogren Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06928142's enrollment target sits among peer trials
83 828th of 2000 higher than 1,171 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI